Oxford Nanopore Technologies and Wasatch BioLabs have joined forces to develop a groundbreaking direct whole-methylome sequencing (dWMS) product. This collaboration addresses the limitations of traditional methylation sequencing methods, such as bisulfite sequencing and methylation microarrays.
By leveraging Oxford Nanopore’s advanced sequencing technology and Wasatch BioLabs’ proprietary methylation assays, the partners aim to offer a more comprehensive and accurate approach to studying epigenetic modifications. dWMS eliminates the need for harsh chemical treatments and PCR amplification, reducing biases and improving genome-wide coverage.
This innovative technology has the potential to revolutionize epigenetic research, providing valuable insights into the role of methylation in various biological processes and diseases. The collaboration between these two companies is poised to drive significant advancements in genomics and precision medicine.